Used in targeted cancer therapies, particularly in the treatment of non-small cell lung cancer (NSCLC). It functions as an irreversible inhibitor of the epidermal growth factor receptor (EGFR), including mutant forms such as T790M and exon 19 deletions, which are associated with tumor growth and resistance to earlier-generation drugs. By selectively blocking EGFR signaling pathways, it suppresses cancer cell proliferation and promotes apoptosis. Its irreversible binding enhances potency and duration of action, making it effective in patients who have developed resistance to other EGFR inhibitors. The compound is designed for oral administration and has shown clinical efficacy in reducing tumor size and improving progression-free survival in advanced stages of the disease.